Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
Morgan R Godin, Preeya K Gupta Department of Ophthalmology, Division of Cornea and Refractive Surgery, Duke University Eye Center, Durham, NC, USA Abstract: A new topical ophthalmic medication, lifitegrast 5%, was recently approved by the US Food and Drug Administration for use in dry eye patients...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-05-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/lifitegrast-ophthalmic-solution-in-the-treatment-of-signs-and-symptoms-peer-reviewed-article-OPTH |
| _version_ | 1819289983282839552 |
|---|---|
| author | Godin MR Gupta PK |
| author_facet | Godin MR Gupta PK |
| author_sort | Godin MR |
| collection | DOAJ |
| description | Morgan R Godin, Preeya K Gupta Department of Ophthalmology, Division of Cornea and Refractive Surgery, Duke University Eye Center, Durham, NC, USA Abstract: A new topical ophthalmic medication, lifitegrast 5%, was recently approved by the US Food and Drug Administration for use in dry eye patients. Lifitegrast is an integrin antagonist that decreases inflammation on the ocular surface, thereby improving dry eye disease (DED). Through a series of prospective, multicenter, randomized, masked, placebo-controlled studies in >2,000 patients total, lifitegrast was shown to be effective for improvement in both the signs and symptoms of DED. A subsequent study focused on the safety profile of lifitegrast and demonstrated that the majority of adverse events were mild and resolved over time. Lifitegrast is now available for use in clinical practice. Keywords: OPUS-1, OPUS-2, OPUS-3, SONATA, LFA-1, ICAM-1, OSDI, ocular surface |
| first_indexed | 2024-12-24T03:15:31Z |
| format | Article |
| id | doaj.art-eccfef0b80344d40b251c2575f854896 |
| institution | Directory Open Access Journal |
| issn | 1177-5483 |
| language | English |
| last_indexed | 2024-12-24T03:15:31Z |
| publishDate | 2017-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-eccfef0b80344d40b251c2575f8548962022-12-21T17:17:39ZengDove Medical PressClinical Ophthalmology1177-54832017-05-01Volume 1195195732973Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapyGodin MRGupta PKMorgan R Godin, Preeya K Gupta Department of Ophthalmology, Division of Cornea and Refractive Surgery, Duke University Eye Center, Durham, NC, USA Abstract: A new topical ophthalmic medication, lifitegrast 5%, was recently approved by the US Food and Drug Administration for use in dry eye patients. Lifitegrast is an integrin antagonist that decreases inflammation on the ocular surface, thereby improving dry eye disease (DED). Through a series of prospective, multicenter, randomized, masked, placebo-controlled studies in >2,000 patients total, lifitegrast was shown to be effective for improvement in both the signs and symptoms of DED. A subsequent study focused on the safety profile of lifitegrast and demonstrated that the majority of adverse events were mild and resolved over time. Lifitegrast is now available for use in clinical practice. Keywords: OPUS-1, OPUS-2, OPUS-3, SONATA, LFA-1, ICAM-1, OSDI, ocular surfacehttps://www.dovepress.com/lifitegrast-ophthalmic-solution-in-the-treatment-of-signs-and-symptoms-peer-reviewed-article-OPTHdry eyeocular surfacelifitegrastOPUS-1OPUS-2OPUS-3SONATALFA-1ICAM-1OSDIODSVAScyclosporine |
| spellingShingle | Godin MR Gupta PK Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy Clinical Ophthalmology dry eye ocular surface lifitegrast OPUS-1 OPUS-2 OPUS-3 SONATA LFA-1 ICAM-1 OSDI ODS VAS cyclosporine |
| title | Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy |
| title_full | Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy |
| title_fullStr | Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy |
| title_full_unstemmed | Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy |
| title_short | Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy |
| title_sort | lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease design development and place in therapy |
| topic | dry eye ocular surface lifitegrast OPUS-1 OPUS-2 OPUS-3 SONATA LFA-1 ICAM-1 OSDI ODS VAS cyclosporine |
| url | https://www.dovepress.com/lifitegrast-ophthalmic-solution-in-the-treatment-of-signs-and-symptoms-peer-reviewed-article-OPTH |
| work_keys_str_mv | AT godinmr lifitegrastophthalmicsolutioninthetreatmentofsignsandsymptomsofdryeyediseasedesigndevelopmentandplaceintherapy AT guptapk lifitegrastophthalmicsolutioninthetreatmentofsignsandsymptomsofdryeyediseasedesigndevelopmentandplaceintherapy |